YellowCard Information Presentation
DES Daughter Network on SlideShare
Member Of Public YellowCard Information Presentation
DES Daughter Network on SlideShare
The Yellow Card Scheme is the main adverse drug reactions reporting scheme in the UK
The MHRA and the Commission on Human Medicines (CHM) run the UK’s spontaneous adverse drug reaction (ADR) reporting scheme – called the Yellow Card Scheme. This receives reports of suspected adverse drug reactions (ADRs) or side effects from healthcare professionals and patients for medicines and vaccines.
The Yellow Card Scheme is the main ADR reporting scheme in the UK and was introduced in 1964 after the thalidomide tragedy highlighted the urgent need for routine monitoring of medicines. It receives about 25,000 reports of possible side effects each year.
Video by emma friedmann, published on 06 Aug 2013
FACSaware aims to raising global awareness of Fetal Anti Convulsant Syndromes and other teratogen-related syndromes. The Fetal AntiConvulsant Trust (F.A.C.T.) was set up in 2011 to campaign for responsibility from the government and drug company.
Topiramate, Valproate Special reminder on risk of neurodevelopmental delay in children following maternal use—not for use in pregnancy
Different antiepileptic drugs (AEDs) vary considerably in their characteristics, which influences the risk of whether switching between different manufacturers’ products of a particular drug may cause adverse effects or loss of seizure control. AEDs have been divided into three risk-based categories to help healthcare professionals decide whether it is necessary to maintain continuity of supply of a specific manufacturer’s product. Read more via the PDF link below.
There is new evidence on neurodevelopmental delay in children following maternal use of sodium valproate. A European review is underway to evaluate all currently available evidence on the association between fetal valproate exposure and neurodevelopmental delay or autism spectrum disorder. Healthcare professionals are reminded that sodium valproate should not be used during pregnancy and in women of childbearing potential unless clearly necessary. Read more via the PDF link below.
Full PDF; read and download the MHRA monthly newsletter
Drug Safety Update November 2013 (Volume 7, Issue 4)
BBC1 Interview with Emma Friedmann of FACSaware
With BBC Panorama Reporter Shelley Jofre
Many women have to take medicines while pregnant. But could they be risking the health of their unborn child? Decades after the Thalidomide scandal shocked the world, Panorama reveals how another medicine has damaged far more children. Drugs cannot be tested on pregnant women for ethical reasons, so doctors do not know if most prescription drugs are safe for the unborn child, and the system set up to monitor side-effects appears to be flawed. As evidence emerges that some common antidepressants are linked to heart defects in babies, the programme asks how much we really know about the safety of medicines women take while pregnant.
Let’s see if the BBC mentions DES following the 2012 DES UK Media Coverage. Find out more about DES exposure and the long-term health effects associated with prenatal exposure to DES drug.
Pips breast implant scandal: Regulator warned years earlier.
A Health Minister review saying that “Lessons must be learned” … I’ve heard that before yet lessons are not learned and history is repeating itself over, and over again …
Read Pips breast implant scandal: Regulator warned years earlier.
The Telegraph, 15 May 2012.